Trovafloxacin

Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D.

INDICATIONS

FDA

Before pulled from the U.S. market for hepatotoxicity reasons, the use of trovafloxacin was reserved for use only if the patient meets all of the following criteria:
- Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
  - Nosocomial pneumonia
  - Community acquired pneumonia
  - Complicated intra-abdominal
  - Gynecologic, pelvic and skin infections
- Receives initial therapy in an in-patient heath care facility (i.e., hospital or long-term nursing care facility).
- The treating physician believes that, even given the new safety information, the benefit of the product for the patient outweighs the potential risk.
- Use of trovafloxacin was limited to 14 days or less.

NON-FDA APPROVED USES

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved